Accuracy of Case-Based Seroprevalence of SARS-CoV-2 Antibodies in Maricopa County, Arizona.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 34936397.
- Also identified by DOI 10.2105/AJPH.2021.306568 and PMC identifier 8713634.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
We conducted a community seroprevalence survey in Arizona, from September 12 to October 1, 2020, to determine the presence of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We used the seroprevalence estimate to predict SARS-CoV-2 infections in the jurisdiction by applying the adjusted seroprevalence to the county's population. The estimated community seroprevalence of SARS-CoV-2 infections was 4.3 times greater (95% confidence interval = 2.2, 7.5) than the number of reported cases. Field surveys with representative sampling provide data that may help fill in gaps in traditional public health reporting. (<i>Am J Public Health</i>. 2022;112(1):38-42. https://doi.org/10.2105/AJPH.2021.306568).
Medical subject headings
- Antibodies, Viral
- COVID-19
- COVID-19 Serological Testing